U.S. Markets closed

Roche's personalized cancer treatment wins FDA approval

Aug 15 (Reuters) - The U.S. Food and Drug Administration approved Roche Holding AG's personalized cancer treatment, the agency said on Thursday.

The treatment, Rozlytrek, is a tyrosine kinase inhibitor that targets patients who must be identified via genetic profiling. The treatment is used to treat certain types of solid tumors and a type of lung cancer.

(Reporting by Aakash Jagadeesh Babu and Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)